Edward Stadtmauer, MD, Section Chief, Hematological Malignancies at the Abramson Center, examines advances in immunotherapy for adult multiple myeloma (MM), acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) as reported at ASCO 2017 and ASH 2016. In this wide-ranging discussion, Dr. Stadtmauer reviews separate studies in pembrolizumab/pom/dex therapy, anti-B-cell maturation antigen (BCMA) therapy, and BCMA-directed chimeric antigen T-cell (CART-BCMA) therapy for relaped/refractory MM.

Related Links: